Document is current

Article History

Received: 21 October 2024

Revised: 29 January 2025

Accepted: 24 February 2025

First Online: 26 March 2025

Competing interests

: KS is a current employee of Gilead Sciences, Inc. All work contributing to this manuscript was performed while at the University of Texas MD Anderson Cancer Center. CY reports no competing interests that are relevant to the findings of this study. MYK reports grants from AbbVie, Allogene, Astra Zeneca, Cellectis, Daiichi, Forty Seven, Genentech, Gilead, MEI Pharma, Precision Bio, Rafael Pharmaceutical, Sanofi, Stemline-Menarini; personal fees from AbbVie, Astra Zeneca, Auxenion, Genentech, Gilead, F. Hoffman-La Roche, Janssen, MEI Pharma, Sellas, Stemline-Menarini. In addition, Dr. Konopleva has a patent US 7,795,305 B2 CDDO-compounds and combination therapies with royalties paid to Reata Pharm., a patent Combination Therapy with a mutant IDH1 Inhibitor and a BCL-2 licensed to Eli Lilly, and a patent 62/993,166 combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof pending to Novartis.

: Primary samples were collected from patients with AML who were treated at The University of Texas MD Anderson Cancer Center. All patients provided their informed consent to donate their peripheral blood and/or bone marrow for research study protocols approved by the MD Anderson Institutional Review Board. All methods were conducted in accordance with the relevant guidelines and regulations.